Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010328 | 0.75 | EPHX2 (0.69) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196107 | 0.75 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL20402859 | 0.71 | EPHX1 (0.83) | EPHX1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL1316952 | 0.68 | EPHX1 (0.77) | EPHX1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL949402 | 0.68 | RIPK1 (0.38) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL8598891 | 0.67 | EPHX1 (0.75) | EPHX1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL8598712 | 0.67 | EPHX1 (0.75) | EPHX1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL4539572 | 0.66 | KDM4E (0.53) | EPHX1EPHX2KDM4EALDH1A1HTT | |
| SCHEMBL4016671 | 0.65 | EPHX2 (0.54) | EPHX1EPHX2 | |
| SCHEMBL10254622 | 0.64 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | GPR119, GLP1R, GIPR | EPHX1 3339/4885EPHX2 2804/4885KDM4E 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.